rsi aegis 8 02 12
DESCRIPTION
Response Scientific®, Inc. is a growth stage company that has developed a patentedmicroencapsulation technology named Aegis Fluidics™ that "shields and protects" the contents of ourmicrocapsules including Rx drugs, Rx medical foods, and nutraceuticals in liquid form, from damaging stomachacids and enzymatic degradation. Protein and peptide derived drugs and nutraceuticals are particularly subject tothis damage.TRANSCRIPT
RESPONSE SCIENTIFIC, INC. (RSI)is a biotechnology company founded in May
2002.
RSI's mission is to improve people's livesthrough innovative research leading to
revolutionarynew healthcare treatments.
5 Independence Way – Suite 300Princeton, New Jersey 08540Contact Gregg Webster, CEO
©2012 RSI
RSI has assembled a stellar scientific advisory boardand personnel to accomplish our mission and
addressthe global health concerns of millions of people.
©2012 RSI
Chairman: Emmanuel C. Opara, PhD.Wake Forest University Medical School
Institute for Regenerative MedicineWinston-Salem, North Carolina
Page 2
Response Scientific’s focus is twofold:
1) Introduce our patented insulin resistance treatment, Receptorex INS2*,
prescription-only medical food to market.
2) Introduce our patented Aegis Fluidics Microencapsulation™ technology
that protects and shields encapsulated drugs, nutraceuticals, Probiotics, and medical foods from damaging stomach acids and enzymatic
degradation
Page 3©2012 RSI
*Code Name
Insulin Resistance Treatment
RSI's insulin resistance small molecule prescription medical food formulation Receptorex INS2* is comprised of liquid GRAS components which reduce ROS imbalance, thereby enhancing insulin sensitivity and lowering the
amount of insulin required to maintain targeted blood glucose levels.
©2012 RSI Page 4
Type 1 and Type 2 Diabetes Discovery
*Code Name
RSI plans to bring this patented prescription medical food
to market in 1Q 2013.
Receptorex INS2* has demonstrated the ability to repair or sensitize damaged insulin receptors and lower the amount of insulin required to maintain healthy blood glucose levels by up to 50%.
Applies to both Type 1 and Type 2 Diabetes patients.
Receptorex INS2* may also delay or even prevent Pre-Diabetes
patients from advancing to full-blown diabetes.
No prescription medication exists today that reduces the amount of exogenous insulin without increasing blood glucose levels.
©2012 RSI Page 5
*Code Name
Receptorex INS2* may also benefit sufferers of Alzheimer’s diseaseand PCOS (polycystic ovarian syndrome) as insulin resistancedirectly affects both of these disease states.
In 2006 researchers at Brown University coined the term Type 3 Diabetes after discovering the insulin resistance link to Alzheimer's.
PCOS is currently treated with Metformin, a diabetes medication. It is important to note that Receptorex INS2* will be the first medication to utilize our newly developed Aegis Fluidics™ Microencapsulation drug delivery technology.
©2012 RSI Page 6
*Code Name
Wholly-Owned Subsidiary of Response Scientific, Inc.
Aegis Fluidics™ is the sales and marketing arm of RSI’s patented
microfluidics encapsulation device and technology.
Hogan Lovells, our patent attorneys, advise that certain products manufactured utilizing our technology may qualify for new
patents.
Developed and Patented byNorth Carolina State University and Biocell Technologies
Exclusive Worldwide Licensee: Response Scientific, Inc.
©2012 RSI Page 7
Aegis Microfluidics capsules Deliver Contents By Diffusion*
The Aegis Microcapsules travel through the stomach to the small intestines virtually unharmedby stomach acids or enzymatic actions. Diffusion of the contents of the microcapsules begins uponentry to the small intestines and continues through the digestive tract releasing contents along the way. Approximately 60% of the contents are emptied in the first 60 minutes.
Diffusion and Concentration Gradients
The passage of the microcapsules through the intestines is dependent on the concentration gradients.A concentration gradient exists whenever a concentrated solution is in contact with a less concentrated solution. Because the solutions are in contact, particles may flow between the two solutions by the process known asdiffusion. Diffusion is a term used to describe the mixing of two different substances that are placed in contact.
Diffusion is the migrating of these different particles. Although particles move in every direction, there is a net flow from the more concentrated solution to the less concentrated solution. As the number of particles in the more concentrated solution diminishes and the number of particles in the less concentrated increases, the differencein concentration between the two solutions decreases. Hence, the concentration gradient is said to get smaller. All else being equal, the concentrations of the solutions change more rapidly when the difference in their concentrations is greater.
This diffusion process continues until the concentrations of the two solutions are equal. This state is known as dynamic equilibrium. When the two solutions are in dynamic equilibrium, particles continue to move between the two solutions, but there is no net flow in any one direction.
While in transit through the digestive tract the Aegis Fluidics Microcapsules never reach equilibriumand therefore continue to empty their contents until the contents are exhausted.
* See drawing next page
Page 8
Bioavailability BreakthroughSuperior Delivery To Bloodstream
Page 9
The patented Aegis Fluidics device allows for the mass production of Prescription Drugs, Prescription Medical Foods & Nutraceuticals.
©2012 RSI Page 10
The resulting microcapsulesare time-released, acid resistant,and not digestible by enzymes,
thus shielding the components fromboth acid and enzymatic degradation.
The Aegis Fluidics™ technology increases bioavailability allowing lower amounts of ingredients
to produce the performance of higher amounts of ingredients.
In light of the economies of scale, the cost savings to major manufacturers of drugs, nutraceuticals and
medical foodsare expected to be substantial.
©2012 RSI
Bioavailability is the amount of a drug that enters the bloodstream. Drugs are considered to have good or poor
bioavailability.
Page 11
ScalabilityThe Aegis Fluidics™ device is easily scalable,
from small testing or sample productionto large mass production volumes for market.
In 2012 RSI will begin to sublicensethis technology to pharmaceutical manufacturers.
©2012 RSI Page 12
The Canadian population is 31,280 million or 10% of the US 10% benchmark is used by Canadian companies wanting to do businessin the US as an estimate of the total business potential. 75% of Canadians live in urban areas. Large urban areas in Canada are:Toronto, Montreal, Ottawa, Vancouver, Edmonton, Calgary, SW Ontario,and the province of Quebec. Canadian urban centers Toronto and Vancouver contain an ever growingAsian population. Asian countries hold tremendous potential. 90% of Canadians live within 100 miles of the US border and are familiarwith US shopping habits, presenting a favorable advantage for marketing dollars. The eastern provinces of Nova Scotia, New Brunswick and Prince Edward Island are considered as having markets and cultures similar to the US.
CANADIAN TEST MARKET
Page 13©2012 RSI
Retail Stores The total Canadian retail market in terms of dollars per yearis $260 billion (multiply x 10 for the US).
Drugs and medicine represent 13.3 billion dollars.
Food sales (grocery stores) count for 59 billion.
Supermarkets count for 55 billion in sales.
Canadian retailers pay their bills within 30 days.
CANADIAN TEST MARKET
Page 14©2012 RSI
Manufacturing
The best location for a Canadian manufacturing facility is along the Ontario 401 highway corridor. The 401 runs from Windsor, Ontario (close to Detroit US) to Ottawa.
The 401 is Canada's busiest highway. A manufacturing location located along the 401 corridor is essential in order to take advantage of the best distribution options available and service the highly populated area of southwestern Ontario. The head offices of mostof Canada's retailers are located in Toronto.
The US is Canada's largest trading partner and the Canadian dollar has been trading on par for the last few months and it is expectedto do so for the next few years. This is an important factor forUS companies doing business in Canada.
CANADIAN TEST MARKET
©2012 RSI Page 15
5 Independence Way – Suite 300, Princeton, New Jersey 08540
Contact Gregg Webster, CEOTel 609-945-4913